PURPOSE: The purpose of this investigation was to examine the effects of a modified version of a newly developed therapy for @entity2026 and acquired @entity1741 ( @entity1741 ), Combined @entity2026 and Apraxia of Speech Treatment (CAAST). METHOD: Four speakers with chronic @entity1741 and @entity2026 received CAAST in the context of multiple baseline designs. Dependent variables included language measures (i.e. production of correct information units (CIUs)) and speech production measures (i.e. speech intelligibility and percent correct consonants (PCC) in sentence repetition). RESULT: Three of the @entity1 demonstrated improved CIU production with treated picture sets and two also demonstrated generalization to untreated sets. All @entity1 achieved substantially increased CIU production in an untrained discourse context. Speech intelligibility increased for three of the @entity1 and increases in PCC were observed for all of the @entity1 at two weeks post-treatment. However, PCC improvements were maintained for only two of the speakers at six weeks post-treatment. CONCLUSION: The revised CAAST protocol was associated with improved changes in speech and generalization across contexts in comparison to the previous iteration of CAAST. However, focus on sentence production in generalization practice may have been detrimental to CIU production for one @entity1 .

Combined @entity2026 and XXXX treatment (CAAST): Systematic replications in the development of a novel treatment.

@entity1741 :: ('OMIM:602081', 'Disease') :: ['apraxia of speech', 'AOS'] @entity1 :: ('9606', 'Species') :: ['participants', 'participant'] @entity2026 :: ('MESH:D001037', 'Disease') :: ['Aphasia', 'aphasia']
@entity1741 :: (OMIM:602081,Disease) :: ['apraxia of speech']
